What is the future of CCR5 antagonists in rheumatoid arthritis?

Tsutomu Takeuchi, Hideto Kameda

研究成果: Editorial査読

8 被引用数 (Scopus)

抄録

Fleishaker and colleagues reported on a double-blind placebo controlled clinical trial of a C-C chemokine-receptor type 5 (CCR5) antagonist, maraviroc, in rheumatoid arthritis (RA) patients with inadequate response to methotrexate, showing that it was ineffective. Two additional CCR5 antagonists, SCH351125 and AZD5672, also failed to demonstrate clinical efficacy. In addition, CCR5-blocking antibodies could not inhibit synovial fluid-induced monocyte chemotaxis. Thus, CCR5 appears not to be a desirable target in RA treatment. Given the multiple functions of CCR5, redundancies in the chemokine system, and patient selection in the trial, we overview the recent understanding for chemokine receptor blockade in the treatment of RA.

本文言語English
論文番号114
ジャーナルArthritis Research and Therapy
14
2
DOI
出版ステータスPublished - 2012 3月 30
外部発表はい

ASJC Scopus subject areas

  • リウマチ学
  • 免疫アレルギー学
  • 免疫学

フィンガープリント

「What is the future of CCR5 antagonists in rheumatoid arthritis?」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル